nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.05.2014 | short review

Follow-up in gastrointestinal cancer

verfasst von: Ulrich Popper, Clemens Dormann, Holger Rumpold, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Follow-up after curative treatment of patients with gastrointestinal cancers aims to detect recurrent disease and to provide curative treatment to prolong overall survival if possible. This, however, has only been shown for colorectal cancers. Regular visits including testing of carcinoembryonic antigen and appropriate staging has been shown to enable curative treatment even in relapse. For other gastrointestinal cancers, positive effects of regular follow-up visits on survival have not been shown so far. This is mostly also due to lacking curative treatment strategies in case of relapse. In these cases, follow-up is recommended for providing palliative treatment, detecting recurrence for quality issues, treating complications or symptoms due to relapse, and providing psychological support. This review will give a brief overview about the current follow-up issues in colorectal, esophagogastric, and pancreatic cancers, as these are clinically the most relevant.

Vorheriger Artikel Follow-up in non-small-cell lung cancer

Nächster Artikel Current therapeutic concepts in mucosa-associated lymphoid tissue (MALT) lymphoma

Cancer Research UK. Cancer statistics—colorectal cancer. http://www.cancerresearchuk.org/cancer-info/cancerstats/world/colorectal-cancer-world/. Accessed 3 May 2013.

Enbald P, Adami HA, Glimelius B, et al. The risk of subsequent primary malignant diseases after cancers of the colon and rectum. A nationwide cohort study. Cancer. 1990;65(9):2091–100.CrossRef

Cali RL, Pitsch RM, Thorson AG, et al. Cumulative incidence of metachronous colorectal cancer. Dis Colon Rectum. 1993;36(4):388–93.PubMedCrossRef

Hermanek P, Jr., Wiebelt H, Riedl S, Staimmer D, Hermanek P. Long-term results of surgical therapy of colon cancer. Results of the colorectal cancer study group. Chirurg. 1994;65:287–97.PubMed

Yamazaki T, Takii Y, Okamoto H, Sakai Y, Hatakeyama K. What is the risk factor for metachronous colorectal carcinoma? Dis Colon Rectum. 1997;40(8):935–8.PubMedCrossRef

Hemminki K, Li X, Dong C. Second primary cancers after sporadic and familial colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001;10(7):793–8.PubMed

Pietra N, Sarli L, Thenasseril BJ, Costi R, Sansebastiano G, Peracchia A. Risk factors of local recurrence of colorectal cancer: a multivariate study. Hepatogastroenterology. 1998;45(23):1573–8.PubMed

Yamamoto S, Akasu T, Fujita S, Moriya Yamamoto S, Akasu T, Fujita S, Moriya Y. Postsurgical surveillance for recurrence of UICC stage I colorectal carcinoma: is follow-up by CEA justified? Hepatogastroenterology. 2005;52(62):444–9.PubMed

Colibaseanu DT, Mathis KL, Abdelsattar ZM, Larson DW, Haddock MG, Dozois EJ. Is curative resection and long-term survival possible for locally re-recurrent colorectal cancer in the pelvis? Dis Colon Rectum. 2013;56(1):14–9.PubMedCrossRef

10.

Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301.PubMedCentralPubMed

11.

Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2013;20(2):572–9.PubMedCrossRef

12.

Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol. 1992;10(6):904–11.

13.

Yamamoto S, Akasu T, Fujita S, et al. Postsurgical surveillance for recurrence of UICC stage I colorectal carcinoma: is follow-up by CEA justified? Hepatogastroenterology. 2005;52(62):444–9.PubMed

14.

Körner H, Søreide K, Stokkeland PJ, et al. Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance. J Gastrointest Surg. 2005;9(3):320–8.PubMedCrossRef

15.

Talbot IC, Ritchie S, Leighton MH, et al. The clinical significance of invasion of veins by rectal cancer. Br J Surg. 1980;67(6):439–42.PubMedCrossRef

16.

Minsky BD, Mies C, Recht A, et al. Resectable adenocarcinoma of the rectosigmoid and rectum. II. The influence of blood vessel invasion. Cancer. 1988;61(7):1417–24.PubMedCrossRef

17.

Krasna MJ, Flancbaum L, Cody RP, Shneibaum S, Ari GB. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer. 1988;61(5):1018–23.PubMedCrossRef

18.

Inoue T, Mori M, Shimono R, et al. Vascular invasion of colorectal carcinoma readily visible with certain stains. Dis Colon Rectum. 1992;35(1):34–9.PubMedCrossRef

19.

Green RJ, Metlay JP, Propert K, et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med. 2002;136(4):261–9.PubMedCrossRef

20.

Harris GJ, Church JM, Senagore AJ, et al. Factors affecting local recurrence of colonic adenocarcinoma. Dis Colon Rectum. 2002;45(8):1029–34.PubMedCrossRef

21.

Merkel S, Meyer T, Gohl J, Hohenberger W. Late locoregional recurrence in rectal carcinoma. Eur J Surg Oncol. 2002;28(7):716–22.PubMedCrossRef

22.

Poulin EC, Schlachta CM, Gregoire R, et al. Local recurrence and survival after laparoscopic mesorectal resection forrectal adenocarcinoma. Surg Endosc. 2002;16(6):989–95.PubMedCrossRef

23.

Bulow S, Christensen IJ, Harling H, et al. Recurrence and survival after mesorectal excision for rectal cancer. Br J Surg. 2003;90(8):974–80.PubMedCrossRef

24.

Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology. 1998;114(1):7–14.PubMedCrossRef

25.

Secco GB, Fardelli R, Gianquinto D, et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol. 2002;28(4):418–23.PubMedCrossRef

26.

Rodriguez-Moranta F, Salo J, Arcusa A, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006;24(3):386–93.PubMedCrossRef

27.

Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum. 1998;41(9):1127–33.PubMedCrossRef

28.

Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma: randomized comparison with no follow-up. Dis Colon Rectum. 1995;38(6):619–26.PubMedCrossRef

29.

Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg. 1997;84(5):666–69.PubMedCrossRef

30.

Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer: results of a prospective randomized trial. Arch Surg. 1995;130(10):1062–7.PubMedCrossRef

31.

Renehan AG, Egger M, Saunders MP, O’Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324(7341):813.PubMedCentralPubMedCrossRef

32.

Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007;(1):CD002200.

33.

Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, George S, Mant D, FACS Trial Investigators. Effect of 3–5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311(3):263–70. doi:10.1001/jama.2013.285718. PubMed PMID: 24430319.

34.

Verberne C, Doornbos PM, Grossmann I, De Bock GH, Wiggers T. Intensified follow-up in colorectal cancer patients using frequent carcino-embryonic antigen (CEA) measurements and CEA-triggered imaging. ESMO congress 2013; Abstr. 2151.

35.

Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC, Habbema JD, van de Velde CJ. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg. 1994;219(2):174–82.PubMedCentralPubMedCrossRef

36.

Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270(8):943–7.PubMedCrossRef

37.

Safi F, Beyer HG. The value of follow-up after curative surgery of colorectal carcinoma. Cancer Detect Prev. 1993;17(3):417–24.PubMed

38.

Zeng Z, Cohen AM, Urmacher C. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients. Dis Colon Rectum. 1993;36(11):1063–8.PubMedCrossRef

39.

Cardoso R, Coburn NG, Seevaratnam R, et al. A systematic review of patient surveillance after curative gastrectomy for gastric cancer: a brief review. Gastric Cancer. 2012;15:19–26.CrossRef

40.

Stahl M, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol. 2013;24(Suppl. 6):51–6.

41.

Waddell T, Verheij M, Allum W, et al. Gastric cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):57–63.

42.

Sheffield KM, Crowell KT, Lin YL, et al. Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol. 2012;19:1670–7.PubMedCentralPubMedCrossRef

43.

Witkowski ER, Smith JK, Ragulin-Coyne E, et al. Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study. J Gastrointest Surg. 2012;16:121–8.PubMedCrossRef

44.

Hishinuma S, Ogata Y, Tomikawa M, et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511–8.PubMedCrossRef

45.

Tzeng CW, Fleming JB, Lee JE, et al. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012;19:2045–53.PubMedCrossRef

46.

Nordby T, Hugenschmidt H, Fagerland MW, et al. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival. Eur J Surg. 2012;39:559–66.CrossRef

47.

Seufferlein T, Bachet JB, Van Cutsem E, et al. Üancreatic adenocarcinoma: ESMO–ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;24(Suppl. 7):33–40.

Titel: Follow-up in gastrointestinal cancer
verfasst von: Ulrich Popper
Clemens Dormann
Holger Rumpold, MD
Publikationsdatum: 01.05.2014
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-014-0152-x

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Follow-up in aggressive lymphomas

Follow-up in melanoma patients

An academic pathological dilemma

Follow-up in non-small-cell lung cancer

Highlights in the prevention of sporadic colorectal cancer

Current therapeutic concepts in mucosa-associated lymphoid tissue (MALT) lymphoma